In most cases (85 percent), the stroke is caused by the occlusion of a blood vessel in the brain. This results in the affected area of the brain becoming undersupplied with blood and oxygen, causing nerve tissue to die off beyond retrieval. Despite intensive research activities, only inadequate treatment options are currently available. The medical engineering company MD-5 GmbH, founded with the support of Fraunhofer IZI, has set itself the goal of improving this situation using an innovative treatment method.
The therapy concept developed by MD-5 GmbH is based on a procedure which can specifically influence the blood flow in the brain using magnetic fields. So-called intelligent transcranial magnetic stimulation (iTMS) allows blood flow to be increased in defined regions of the brain, thus limiting damage caused by a stroke. “Several investigations and optimizations are still required before the technology can be introduced into clinical routine as a medical device. Together with the Fraunhofer IZI and Leipzig University Hospital, we look forward to continuing with the development of a prototype which is suitable for practice and preparing its market launch,” commented Dr. Mark K. Borsody, Founder and Chief Medical Officer, describing the cooperation work of the joint project.
“The Fraunhofer IZI is contributing its comprehensive expertise in the areas of stroke research and preclinical development. Expressive model systems are to verify both the safety and efficacy of the procedure. The procedure can then be optimized accordingly by our colleagues at MD-5, based on these investigations,” commented Dr. Antje Dreyer, Head of the Clinic-oriented Therapy Assessment Unit at Fraunhofer IZI, describing the Fraunhofer Institute's role in the project.
With the addition of MD-5 GmbH, founded in Leipzig in October 2012 as a subsidiary of the US company Lake Bioscience LLC, Fraunhofer IZI has managed to bring on board another international partner and increase investment in the biotechnology location of Saxony.
“We are very glad that we succeded in convincing our colleagues from Lake Biosciences to establish their european subsidiary in Leipzig / Saxony” adds Dr. Thomas Tradler, Head of Business Development at the Fraunhofer IZI.
The project, valued at a total of 1.4 million euros, is being funded through the Sächsische Aufbaubank (Saxon Development Bank) with a total of 1.1 million euros coming from the European Regional Development Fund (ERDF) and also from the Free State of Saxony.
The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops specific problem solutions at the interfaces of medicine, life sciences and engineering. The Institute practices contract research for biotechnological, pharmaceutical and medical-technological companies, hospitals, diagnostic laboratories and research facilities. Within the Business Units of Agents, Cell Therapy, Diagnostic and Biobanking, the Institute develops, optimizes and validates methods, materials and products. The Institute's core competencies are located in the field of Regenerative Medicine, in particular in the indication areas of oncology, ischemia and autoimmune, inflammatory and infectious diseases. The Institute is clinically oriented and conducts quality checks and the GMP-compliant manufacture of investigational medicinal products. Moreover, the Institute provides support in obtaining manufacturing authorizations and approvals.
Virtual Reality in Medicine: New Opportunities for Diagnostics and Surgical Planning
07.12.2016 | Universität Basel
3-D printed kidney phantoms aid nuclear medicine dosing calibration
06.12.2016 | Society of Nuclear Medicine
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine